Flexibility, capacity and expanded menu plus the ability to run laboratory developed tests.
Add on the power to run real-time PCR, TMA and RT-TMA assays on a single, fully automated platform. With the Panther Fusion module you can consolidate testing, increase walkaway time and enhance flexibility.
-
Up to 32 assay reagent kits on board, which allow assay consolidation on a single platform.
-
Ready-to-use reagent cartridges reduce manual preparation and operator errors.
-
Sample throughput up to 500 tests in 8 hours increases test volume in a shift without increasing staff.
-
Minimal hardware/software changes allow additional testing without extensive retraining or SOP updates.
-
Open Access™ functionality provides full automation to run laboratory developed tests with IVDs.
-
Time-to-first result at 2.4 hours allows patient results to be released sooner and improves turnaround time.
- Add on additional IVD menu without disrupting existing workflow.
-
Run up to 5 PCR reactions from a single (360μL) patient extraction, reducing extraction time and costs.
-
60-day onboard stability of reagents and fluids minimizes reagent waste for better cost management.
-
Utilize existing Panther system LIS connection for Panther Fusion assays, reducing LIS costs.
-
In-lab upgrade increases test volumes, throughput and menu without replacing equipment or infrastructure.
Consolidate Your Assay Menu
The Aptima® and Panther Fusion assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.
Assays that run on the Panther Fusion System
Women's Health
Infectious Disease
CMV†
EBV
BKV
SARS-CoV-2/Flu/A/B/RSV†
GI Bacterial†
GI Extended Bacterial†
GI Viral†
GI Parasite†
References
* The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
† In Development and not for sale
Related Products
Flexibility, capacity and expanded menu plus the ability to run laboratory developed tests
Add on the power to run real-time PCR, TMA and RT-TMA assays on a single, fully automated platform. With the Panther Fusion® module you can consolidate testing, increase walkaway time and enhance flexibility.
-
Up to 32 assay reagent kits on board, which allow assay consolidation on a single platform
-
Ready-to-use reagent cartridges reduce manual preparation and operator errors
-
Sample throughput up to 500 tests in 8 hours increases test volume in a shift without increasing staff
-
Minimal hardware/software changes allow additional testing without extensive retraining or SOP updates
-
Open Access™ functionality provides full automation to run laboratory developed tests with IVDs
-
Time-to-first result at 2.4 hours allows patient results to be released sooner and improves turnaround time
- Add on additional IVD menu without disrupting existing workflow
-
Run up to 5 PCR reactions from a single (360μL) patient extraction, reducing extraction time and costs
-
60-day onboard stability of reagents and fluids minimizes reagent waste for better cost management
-
Utilize existing Panther® system LIS connection for Panther Fusion® assays, reducing LIS costs
-
In-lab upgrade increases test volumes, throughput and menu without replacing equipment or infrastructure
Consolidate your assay menu
The Aptima® and Panther Fusion assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.
Assay that run on the Panther Fusion System
Women's Health
Infectious Disease
CMV†
EBV†
BKV†
SARS-CoV-2/Flu/A/B/RSV†
GI Bacterial
GI Extended Bacterial
GI Viral†
GI Parasite†
* The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
† In Development and not for sale
Related Products
